CRFR1 activation protects against cytokine-induced β-cell death

Lykke Blaabjerg1,2,*; Gitte L Christensen2,*, Masahito Matsumoto1, Talitha van der Meulen1, Mark O Huising1, Nils Billestrup2 and Wylie W Vale1

1Clayton Foundation Laboratories for Peptide Biology, Salk Institute, 10100 North Torrey Pines Road, La Jolla, California 92037, USA
2Cellular and Metabolic Research Section, Department of Biomedical Sciences, Faculty of Health Sciences, University of Copenhagen, Blegdamsvej 3, 2200 Copenhagen N, Denmark

*(L Blaabjerg and G L Christensen contributed equally to this work)

Correspondence should be addressed to L Blaabjerg
Email lykke@blaabjerg.net

Abstract
During the development of diabetes β-cells are exposed to elevated concentrations of proinflammatory cytokines, TNFα and IL1β, which in vitro induce β-cell death. The class B G-protein-coupled receptors (GPCRs): corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2 are expressed in pancreatic islets. As downstream signaling by other class B GPCRs can protect against cytokine-induced β-cell apoptosis, we evaluated the protective potential of CRFR activation in β-cells in a pro-inflammatory setting. CRFR1/CRFR2 ligands activated AKT and CRFR1 signaling and reduced apoptosis in human islets. In rat and mouse insulin-secreting cell lines (INS-1 and MIN6), CRFR1 agonists upregulated insulin receptor substrate 2 (IRS2) expression, increased AKT activation, counteracted the cytokine-mediated decrease in BAD phosphorylation, and inhibited apoptosis. The anti-apoptotic signaling was dependent on prolonged exposure to corticotropin-releasing factor family peptides and followed PKA-mediated IRS2 upregulation. This indicates that CRFR signaling counteracts proinflammatory cytokine-mediated apoptotic pathways through upregulation of survival signaling in β-cells. Interestingly, CRFR signaling also counteracted basal apoptosis in both cultured INS-1 cells and intact human islets.

Key Words
- β cells
- apoptosis
- survival
- urocortins
- GPCR
- CRFR
- cytokines

Introduction
Pancreatic β-cell death occurs in type 1 as well as type 2 diabetes mellitus, leading to a progressive decline in β-cell function and β-cell mass. Although the initiating mechanism differs, some signaling pathways are relevant to both types of diabetes as they converge on common effectors. This is true for interleukin 1 beta (IL1β) and tumour necrosis factor alpha (TNFα) signaling, as both these pathways lead to the activation of two key pro-apoptotic signaling pathways in the β-cell, i.e. nuclear factor kappa B (NFkB) and MAPKs (Donath et al. 2003). Before cytokine exposure, NFkB is sequestered in the cytoplasm bound to inhibitor protein kappa Bz (IxBz). Following IL1β or TNFα exposure, IxBz is phosphorylated, ubiquitinated, and degraded by the proteasomal complex, liberating NFkB to translocate to the nucleus and induce the expression of several inflammatory genes (Baldwin et al. 1996, Flodstrom et al. 1996, Heimberg et al. 2001, Patel & Santani 2009). Inhibition of the NFkB pathway protects pancreatic β-cells from cytokine-induced apoptosis in vitro and from multiple low-dose streptozotocin (STZ)-induced diabetes in vivo (Patel & Santani 2009).
The c-Jun N-terminal kinase (JNK) is a member of the MAPKs and an important mediator of cytokine-induced β-cell death. Blockage of JNK signaling protects against IL1β-induced apoptosis in insulin-secreting cells (Ammendrup et al. 2000, Bonny et al. 2000, 2001, Nikulina et al. 2003) and prevents cytokine-induced suppression of viability in human islets (Aikin et al. 2004). Two other MAPKs, ERK1/2 and p38, have also been shown to be involved in the mediation of deleterious cytokine effects in β-cells (Pavlovic et al. 2000, Saldeen et al. 2001), although ERK1/2 may be more known for its proliferative capacity (Blandino-Rosano et al. 2008). The cross-talk between JNK and the serine/threonine kinase AKT has a great effect on the survival prospects of human islets (Aikin et al. 2004). AKT is widely involved in cell growth and survival and its importance in β-cell survival has been substantiated using various mouse models with transgenic modification of components of the AKT pathway (Elghazi & Bernal-Mizrachi 2009). AKT is commonly activated in a phosphatidylinositol 3-kinase (PI3K)-dependent manner (Elghazi & Bernal-Mizrachi 2009). The insulin receptor substrate 2 (IRS2), a substrate of the insulin/insulin-like growth factor signaling cascade responsible for compensatory β-cell growth, function, and survival throughout life (Jhala et al. 2003, White 2003), mediates anti-apoptotic signaling through the activation of AKT. A correlation between the increase in cAMP levels and the IRS2/AKT signaling pathway in β-cells has been demonstrated (Jhala et al. 2003, Van de Velde et al. 2011). AKT signaling inhibits several pro-apoptotic components including the JNK pathway (Aikin et al. 2004) and the pro-apoptotic BCL2 family member BAD (Zha et al. 1996). AKT-induced BAD phosphorylation is antagonized by JNK-stimulated BAD dephosphorylation. The latter leads to BAD-mediated functional blockage of anti-apoptotic BCL-Xl and BCL2, initiation of the caspase cascade, and induction of β-cell death (Zha et al. 1996, Sunayama et al. 2005).

The corticotropin-releasing factor (CRF) family of peptides includes CRF, and urocortin (UCN) 1, 2, and 3 (Vaughan et al. 1995, Perrin & Vale 1999, Reyes et al. 2001, Lewis et al. 2001). These peptides bind to the two subtypes of CRF receptors, corticotropin-releasing factor receptor 1 (CRFR1) and CRFR2, with varying affinity. CRF is a preferred CRFR1 agonist (Perrin & Vale 1999) in contrast to UCN2 and UCN3, which are selective CRFR2 agonists (Hsu & Hsueh 2001, Lewis et al. 2001, Reyes et al. 2001). UCN1 binds to both receptors with high affinity (Perrin & Vale 1999). The members of this family were initially recognised as coordinators of the mammalian stress response. Since then, these peptides as well as their receptors have been identified in many tissues throughout the periphery, indicating a potential involvement in other physiological responses (Kimura et al. 2002, Florio et al. 2004, Feke & Zorrilla 2007, Kuperman & Chen 2008, Lee et al. 2011). In fact, the pancreatic β-cell is one of the most abundant sites of UCN3 expression (Li et al. 2003).

Pancreatic islets were recently found to express both CRFR1 and CRFR2 in equal abundance (Huising et al. 2011). In clonal β-cells, such as MIN6 and INS-1 cells, the expression levels of CRFR1 are much higher than those of CRFR2, a balance that can be overturned by exposure to glucocorticoids (Huising et al. 2010, 2011). These receptors belong to the class B G-protein-coupled receptors (GPCRs), as do receptors for incretins such as glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP1) (Brubaker & Drucker 2002). This subclass of receptors couples with Gαs and activates adenylyl cyclase to stimulate cAMP production. We have previously shown that CRFR1 activation increases insulin secretion from the pancreatic islets (Huising et al. 2010). The signaling induced by GIP and GLP1 is known to prevent cytokine-induced apoptosis in β-cells (Li et al. 2005, Ferdaoussi et al. 2008, Natalicchio et al. 2010), prompting us to investigate the potential of CRFR signaling to promote β-cell survival and to protect against cytokine-induced β-cell death.

Materials and methods

Reagents

Recombinant murine IL1β was purchased from BD Pharmingen (San Diego, CA, USA) and mouse TNFα from R&D Systems (Minneapolis, MN, USA). Antalarmin was a kind gift from Dr Chrousos at the NIH. All peptides used in this study were synthesized using BOC chemistry and provided by Dr Jean Rivier (The Salk Institute, La Jolla, CA, USA). LY294002 and H89 were obtained from Calbiochem (Billeria, MA, USA).

Cells

INS-1 cells and MIN6 insulinoma cells (obtained at passage 18 from Ulupi Jhala (UCSD, La Jolla, CA, USA) were maintained in DMEM (Invitrogen), containing Glutamax and 11 mM of glucose and supplemented with 10% FBS (Sigma), 100 U/ml penicillin, 100 µg/ml streptomycin (Invitrogen), and 10 µmol/l β-mercaptoethanol (Sigma). The cells were cultured under standard cell culture conditions at 37 °C in a humidified atmosphere containing 5% CO2.
Human islets

Human islets were obtained through the Integrated Islet Distribution Program (IIDP islet program) funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and with support from the Juvenile Diabetes Research Foundation International (JDRFI). Upon arrival, islets were washed twice in CMRL with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). The islets were re-picked and cultured for 1–2 days before an experiment was set up.

Immunoblotting

One hundred human islets were seeded into 24-well plates (Nunc, Rochester, NY, USA) or 400 000 INS-1 cells were seeded into 12-well plates. The receptor antagonists were added 30 min before peptides and cells/islets were incubated for various times (30 min to 24 h). The cytokines were added 16 h following peptide treatment and cultured continued for another 20 min to 24 h. The cells were lysed in PLC-lysis buffer (50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 10 mM NaPPi, 7.5), 150 mM NaCl, 10% glycerol, 1% Triton X-100, 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen). The islets were re-picked and cultured for 1–2 days before an experiment was set up.

Gene reporter assay

Two hundred thousand INS-1 cells were seeded in triplicates into 24-well dishes and preincubated for 2 days. On the day of transfection, the medium was discarded and the cells transiently co-transfected with a total of 0.7 μg plasmid DNA using Lipofectamin 2000 (Invitrogen): NFκB-dependent expression plasmid (Strategene, Santa Clara, CA, USA) together with a β-galactosidase expression plasmid for normalization. Following 6 h of transfection, the media was replaced and cells were cultured overnight before the addition of cytokines for 4 h. The cells were subsequently washed in HDB and lysed in Gly–Gly buffer (25 mM Gly–Gly (pH 7.5), 15 mM MgSO4, 4 mM EGTA), with the addition of 10% Triton X-100 and 1 mM DTT. At the time of measurements, the samples were diluted in Gly–Gly buffer including 10 mM potassium phosphate, 1.25 mM DTT, and 1.25 mM ATP. Luciferase activity was detected by adding Gly–Gly buffer containing 0.1 mM luciferase and read using a Modulus plate reader. Consecutively, β-galactosidase buffer (0.875 mg/ml O-nitrophenyl-β-D-galactoside (ONPG) in sodium phosphate, 100 mM sodium phosphate pH 7.5, 0.3% β-mercaptoethanol, 1 mM MgCl2) was added and cells were incubated until a color change was observed and the absorbance was measured at 450 nM.

Cell death detection ELISA

Sixty human islets or 200 000 INS-1 cells were seeded in 24-well plates. Following pre-treatment with peptides, cells or islets were cultured in the presence or absence of cytokines for 6 days or 24 h respectively. The degree of apoptosis was measured by cell death detection ELISA plus (Roche) according to the manufacturer’s instructions, detecting the amount of DNA-histone complexes present in the cytoplasmic lysates.

Statistical analyses

All data are presented as mean±S.E.M. of n independent experiments. Statistical analysis was performed using a paired Student’s t-test or a one-way ANOVA followed by post hoc Dunnett multiple comparison analysis where appropriate. A P value <0.05 was considered significant.
Results

CRF family members differentially activate AKT in β-cells

AKT has previously been shown to be involved in β-cell survival signaling mediated by class B GPCRs, and we investigated whether members of the CRF family could affect AKT activity in β-cells. INS-1 cells were treated with the CRFR1-selective agonist, ovine CRF (oCRF), for various times ranging from 0 to 24 h. A time-dependent increase in phosphorylation of AKT, peaking at around 16 h of oCRF exposure was demonstrated (Fig. 1a). The experiment was repeated using either mouse UCN3 (mUCN3) or rat UCN1 (rUCN1) to activate either CRFR2 alone or both CRFR1 and CRFR2, simultaneously. Exposure of cells to rUCN1 for 16 h robustly upregulated the levels of phosphorylated AKT compared with untreated cells, as seen for oCRF (Fig. 1b and c for rat INS-1 and mouse MIN6 cells, respectively). In contrast no effect was observed with mUCN3.

CRFR1-mediated upregulation of IRS2 and PI3K-dependent activation of AKT in β-cells

β-cells, as opposed to intact islets, mainly express CRFR1 and pre-incubating the cells with 10 μM of the CRFR1-selective antagonist antalarmin fully blocked both basal and oCRF- and rUCN1-mediated phosphorylation of AKT, suggesting that this is a CRFR1-mediated effect (Fig. 2a).

As PI3K is a common upstream activator of AKT, we used LY294002, a pharmacological inhibitor of PI3K signaling, to investigate whether PI3K was involved in AKT activation in our cell systems. As evident from Fig. 2b, pre-incubation with 10 μM of LY294002 fully inhibited oCRF- and rUCN1-mediated phosphorylation of AKT. In addition, we found that oCRF dose-dependently affected transcription of a glucose-6-phosphatase promoter construct in a luciferase assay, a promoter previously reported to be responsive to the activation of the AKT signaling pathway (Schmoll et al. 2000; Fig. 2c), further confirming activation of the AKT pathway.

CRFR1 activation did not lead to acute activation of AKT in β-cells (Fig. 1), indicating that the observed effects are dependent on another factor. IRS2 is thought to promote islet cell survival in response to insulin and IGFI signaling (Withers et al. 1999, Fernández et al. 2007) and may act upstream of PI3K (Jhala et al. 2003). To investigate if CRFR1 agonists could increase IRS2 expression in β-cells, INS-1 cells were treated with oCRF or rUCN1 for various times, ranging from 30 min to 24 h. From the results of this experiment, we conclude that CRFR1 activation leads to increased protein levels of IRS2, peaking at around 8 h of treatment (Fig. 2d). Pre-treating the cells with 10 μM of H89, a pharmacological inhibitor of the cAMP-dependent protein kinase A (PKA), before exposure to the CRFR1 ligands revealed partial inhibition of oCRF- or rUCN1-induced upregulation of IRS2 protein expression and AKT phosphorylation (Fig. 2e). Together these results indicate that CRFR1-mediated PKA-dependent upregulation of IRS2 precedes AKT activation.

CRFR1 activation increases survival signaling in cytokine-exposed β-cells

The pro-inflammatory cytokines IL1β and TNFα have been shown to induce apoptosis by inhibiting the activity of AKT. As seen in Fig. 3a, exposure to IL1β (160 pg/ml) or TNFα (20 ng/ml) for 24 h reduced the levels of phosphorylated AKT compared with those for untreated INS-1 cells. To examine if CRFR1 activation preserves AKT activity in the presence of cytokines, INS-1 cells were
pre-treated with oCRF, rUCN1, or mUCN3 for 16 h, followed by exposure to IL1β or TNFα. Cytokine-induced reduction of phosphorylated AKT was counteracted by pre-treatment with either oCRF or rUCN1. In line with previous observations, we did not observe any protection against the cytokine-mediated decrease in AKT phosphorylation with mUCN3 treatment.

One mechanism by which AKT promotes survival is by phosphorylation-induced inactivation of the pro-apoptotic BAD. Indeed, exposure of INS-1 cells to TNFα partly reduced the levels of phosphorylated BAD compared with untreated INS-1 cells (Fig. 3b) and as for AKT, cytokine-mediated reduction in phosphorylated BAD was counteracted by pre-culturing the cells in the presence of oCRF or rUCN1 but not by mUCN3. A similar effect was seen after exposure of INS-1 cells to IL1β or MIN6 cells to a combination of IL1β and TNFα (data not shown). We thus conclude that CRFR1 agonists can increase survival signaling and inhibit cytokine-mediated apoptosis.

CRFR1 activation counteracts pro-apoptotic signaling in cytokine-exposed β-cells

The MAPKs are activated by cytokines such as IL1β and TNFα. To explore any potential effects of CRFR activation on MAPK activity, INS-1 cells were pre-treated with CRF family members as described above and subsequently exposed to either IL1β or TNFα for an additional 20 min. Western blotting results represented in Fig. 4a indicate that, as expected, cytokines activated all three MAPKs. Neither peptide inhibited MAPK phosphorylation, but interestingly cytokine-induced ERK1/2 phosphorylation was potentiated in cells pre-treated with oCRF or rUCN1. No effect was seen for mUCN3.
CRFR1 activation prevents cytokine-induced apoptosis

As CRFR1 activation affects key survival and apoptotic pathways, we next explored the effect of cytokines and the CRF family members on cleavage of the executor caspase 3. Stimulation with a combination of IL1β and TNFα resulted in the cleavage of caspase 3 (Fig. 5a). We found that pre-treatment with either oCRF or rUCN1 but not mUCN3 reduced this cytokine-mediated cleavage of caspase 3, supporting the concept that activation of the CRFR1 protects against cytokine-induced β-cell death.

Figure 3
Effect of CRFR signaling on survival pathways. (a) INS-1 cells were pre-cultured with oCRF, rUCN1, or mUCN3 for 16 h. Subsequently, IL1β (160 pg/ml) or TNFα (20 ng/ml) was added to the cells and culture was continued for another 24 h. The cell extract was analysed for phosphorylated (P-AKT) or total (T-AKT) AKT by western blotting analysis. A representative blot is shown (n = 5). (b) INS-1 cells were pre-treated as described above and exposed to TNFα for 24 h. Levels of phosphorylated BAD and β-actin were analysed by western blotting analysis. A representative blot from one of three independent experiments is shown (n = 3).

Taking advantage of an NFκB-reporter construct, we looked at NFκB-mediated gene regulation. As expected, both IL1β and TNFα significantly increased NFκB promoter activity in INS-1 cells (Fig. 4b). The cells pre-treated with oCRF exhibited lesser cytokine-mediated increases in promoter activity, indicating that CRFR1 activation can affect cytokine-induced NFκB-mediated gene regulation. TNFα and IL1β increase NFκB transcriptional activity by promoting IκBα degradation. However, neither peptide was able to inhibit this cytokine-induced degradation of IκBα, indicating that CRF family members do not exert their modulation of NFκB signaling by affecting IκBα directly (Fig. 4c). Similar results were obtained using MIN6 cells (data not shown).

Figure 4
Effect of CRFR signaling on cytokine-induced MAPK and NFκB activation. (a) INS-1 cells were pre-cultured with oCRF, rUCN1, or mUCN3 for 16 h followed by IL1β (160 pg/ml) or TNFα (20 ng/ml) exposure for an additional 20 min. The cell extracts were analysed for phosphorylated (P) JNK, p38, and ERK1/2. A representative blot from three independent experiments is shown (n = 3). (b) INS-1 cells were transiently co-transfected with an NFκB-responsive reporter construct together with a constitutively active β-galactosidase construct, incubated with oCRF for 16 h and exposed to IL1β or TNFα for another 6 h. Data are presented as mean luciferase activity normalised to β-galactosidase ± S.E.M. from four independent experiments each carried out in triplicates (n = 4). *P < 0.05 vs cytokine-treated cells (t-test). White bars represent controls, black bars IL1β-treated, and grey bars TNFα-treated cells. (c) INS-1 cells were treated as described above and degradation of IκBα was analysed by western blotting analysis using the whole-cell lysates and antibodies against IκBα and the housekeeping protein β-actin. A representative blot from one of three independent experiments is shown (n = 3).
CRFR1 prevents cytokine-induced β-cell death

To confirm this, we evaluated β-cell apoptosis in the form of DNA double-stranded breaks by using the cell death detection ELISA assay. This assay revealed an increase in apoptosis in INS-1 cells following TNFα exposure for 24 h. Pre-treating the cells with either oCRF or rUCN1 completely blocked TNFα-induced apoptosis (Fig. 5b). Similarly, oCRF or rUCN1 but not mUCN3 significantly inhibited IL1β- or TNFα-induced apoptosis in MIN6 cells (Fig. 5c). Taking a closer look at basal apoptosis, oCRF and rUCN1 also inhibited basal apoptosis in INS-1 cells (Fig. 5d). This effect was counteracted by 30 min pretreatment with the CRFR1-selective antagonist antalarmin (Fig. 5d).

CRFR1 and CRFR2 activation promote basal survival of human islets

The effect of CRFR1 and CRFR2 activation was investigated in human islets from three individual donors. Intact human islets were cultured in the presence of oCRF, rUCN1, or hUCN3 and cell lysates analysed for phosphorylation of AKT. As is evident from Fig. 6a, AKT phosphorylation was apparent in response to both CRFR1 and CRFR2 ligands following 8–16 h of treatment (Fig. 6a).

In human islets from one donor oCRF, rUCN1, or hUCN3 reduced apoptosis induced by a combination of IL1β, TNFα, and IFNγ by 49, 17, and 42% respectively (data not shown). In experiments using islets from two other donors, cytokines induced substantially more apoptosis, which could not be inhibited by the CRF family members tested (data not shown). However, in islets from all three donors, basal apoptosis levels in freshly isolated human islets were significantly reduced when cultured in the presence of oCRF or rUCN1 (Fig. 6b). Human UCN3 did not significantly reduce apoptosis (P=0.06). These results indicate that the CRFR1-selective agonists can activate AKT and inhibit apoptosis in cultured human islets.

Discussion

In this study, we characterized CRFR signaling in β-cells and examined the role of CRF family members in cytokine-induced β-cell apoptosis. Signaling through

Figure 5

Effects of CRFR1 signaling on cytokine-induced apoptosis. (a) MIN6 cells were pre-treated with 50 nM of oCRF, rUCN1, or mUCN3 for 16 h. Subsequently cells were exposed to IL1β (160 pg/ml) in combination with TNFα for 24 h. Following lysis, western blotting was carried out and apoptosis was detected by antibodies recognising the cleaved form of caspase 3 as well as β-actin. A representative blot from one of three independent experiments is shown (n=3). (b) INS-1 cells were pre-treated as described for (a) subsequently TNFα (20 ng/ml) or was added and cells were cultured for another 24 h. (c) MIN6 cells were treated as described above and exposed to IL1β (160 pg/ml) or TNFα (20 ng/ml) for 24 h. (d) INS-1 cells were pretreated with vehicle (EtOH) or 5 μM antalarmin for 30 min before stimulation with 50 nM oCRF or rUCN1 for 60 h. Apoptosis was detected by cell death detection ELISA and data are presented as mean fold induction of apoptosis ± S.E.M. from three to four independent experiments (n=3–4). *P<0.05, **P<0.01, ***P<0.001 vs cytokine-stimulated cells (t-test). White bars represent controls, black bars TNFα-treated cells, and grey bars IL1β-treated cells.

Figure 6

Effect of CRFR signaling on human islets. (a) Human islets were pre-treated with 50 nM of oCRF, rUCN1, or hUCN3 as indicated and analysed for levels of phosphorylated AKT (P-AKT) or total AKT (T-AKT) by western blotting analysis. A representative blot from one of three independent experiments is shown (n=3). (b) Human islets were pre-treated as described above and cultured for 6 days. Apoptosis was determined by the cell death detection ELISA. Experiment was carried out independently on islets from three different donors and data are presented as mean apoptosis ± S.E.M. *P<0.05, **P<0.01 vs untreated islets (t-test) (n=3).
CRFR1 and CRFR2 protects cultured hippocampal and neocortical neurons from a range of neurotoxic mediators (Facchi et al. 2003) and positively affects survival of cardiac myocytes in the models of heart failure (Brar et al. 2000, 2002). Recently, CRF has been shown to inhibit basal apoptosis in INS-1 cells following 72 h of culture, but the underlying mechanisms were not investigated (Schmid et al. 2011). In this study, we confirm this observation using both cell lines and human islets and demonstrate for the first time, to our knowledge, the ability of the CRF family members to protect β-cells against apoptotic stimuli associated with the development of diabetes.

Inhibition of pro-apoptotic NFκB signaling was apparent as CRFR1 activation reduced NFκB-mediated gene transcription induced by either TNFα or IL1β. No effect was seen on IkBα degradation. The ability of NFκB to recruit the transcriptional apparatus and stimulate target gene expression in the nucleus is ensured by post-translational modification (i.e., phosphorylation, acetylation, etc.) of NFκB itself and its surrounding chromatin environment. CRFR1 agonists may inhibit NFκB-mediated gene transcription by preventing crucial post-translational modifications, although this has not been investigated further.

In addition, CRFR1 signaling prevented the cytokine-mediated decrease in AKT phosphorylation as well as dephosphorylation of the AKT target BAD, all favoring survival.

A time-course experiment revealed that a prolonged exposure (16 h) to CRFR1 ligands was required for robust activation of AKT in β-cells. This is in line with what has been reported for GLP1-receptor-mediated AKT activation in MIN6 cells and human islets. The proposed mechanism involved is a AMP/PKA and CREB-dependent upregulation of IRS2 protein levels working upstream of PI3K (Jhala et al. 2003, Li et al. 2005, Park et al. 2006, Altarejos & Montminy 2011, Van de Velde et al. 2011, Velmurugan et al. 2012). We have previously demonstrated a robust CRFR1-mediated increase in CREB phosphorylation (Huising et al. 2010) and in the current study revealed a time- and PKA-dependent increase in IRS2 protein expression following CRFR1 activation in INS-1 cells peaking before maximum AKT activation.

CRFR1 and CRFR2 belong to the same receptor class as that of receptors for incretins, such as GLP1. GLP1 has been shown to inhibit β-cell apoptosis, and protection against cytokine-induced apoptosis was correlated with inhibition of JNK activity (Ferdaoussi et al. 2008, Natalicchio et al. 2010), but no effect was observed on p38 activity.

As for GLP1, we did not observe any effect of CRFR1 activation on p38 activity; however, we did not detect any inhibitory effect of any of the peptides on JNK phosphorylation in INS-1 cells. In MIN6 cells, TNFα-induced JNK activation was inhibited by CRFR1 agonists (data not shown), indicating some discrepancies between the signaling in these two cell lines. In both cell types, CRFR1 ligands protected against apoptosis induced by exposure to either cytokine individually or in combination, implying that inhibition of JNK activity is not decisive for β-cell survival under these conditions. Surprisingly, cytokine-induced ERK1/2 phosphorylation was potentiated by CRFR1 agonists in INS-1 cells. Cytokine-induced ERK1/2 phosphorylation has previously been linked with cytokine-induced nitric oxide formation and β-cell apoptosis. However, ERK1/2 is generally involved in the regulation of proliferation (Blandino-Rosano et al. 2008) and our previous results indicated that CRF-induced ERK1/2 activation was associated with increased β-cell proliferation in neonatal rat islets (Huising et al. 2010). Whether increased ERK1/2 activation following short-term exposure to cytokines acts as a survival/proliferative mechanism which is potentiated by the presence of CRFR1 agonists remains to be investigated.

Throughout the study, we observed no protective effect of the CRFR2-selective agonist UCN3 on clonal β-cells, INS-1, and MIN6. However, in intact human islets, UCN3 robustly activated AKT but did not significantly reduce apoptosis (P = 0.06). This is in agreement with our published observations indicating relatively low expression of CRFR2 on clonal β-cell lines as opposed to primary rodent and human islets (Huising et al. 2011). UCN3 itself is abundantly expressed in β-cells and regulates glucose-stimulated insulin secretion and energy homeostasis (Li et al. 2007). These observations strongly indicate that UCN3 plays important roles in the regulation of β-cell function in vivo. Furthermore, CRFR2 expression is robustly upregulated in both primary islets and clonal β-cells in response to glucocorticoids, increasing the sensitivity of UCN3 (Huising et al. 2010). This study also revealed that basal expression of CRFR2 is insufficient to mediate the ligand-induced response in INS-1 and MIN6 cells, but it is likely that conditions with increased CRFR2 levels would enable UCN3 to promote β-cell survival in a manner similar to agonists of CRFR1.

By testing three different batches of human islets, we consistently observed CRFR1-mediated inhibition of basal apoptosis, in line with our data on INS-1 cells. In addition, CRFR1 as well as CRFR2-signaling decreased cytokine-induced apoptosis in islets from one of the donors. Human islets from the other two donors exhibited a more robust
induction of apoptosis in response to the combination of TNFα, IL1β, and IFNγ for 6 days, and CRFR activation was not capable of protecting against cytokine-induced apoptosis in these islets (data not shown). The considerable variation in islet function and quality from preparation to preparation is a well-known concern when using human islets for experiments, indicating that additional batches of human islets and perhaps lower concentrations of or shorter exposure to cytokines are needed to explore the potential of CRF family members to protect against cytokine-induced apoptosis in human islets.

Conclusion

The results of this study indicate that CRFR1 signaling promotes β-cell survival and protects β-cells from the negative consequences of pro-inflammatory cytokines. The outcome of CRFR1-mediated signaling pathways is a shift in the balance between pro- vs anti-apoptotic signaling pathways toward increased β-cell survival. Activation of intracellular stress signaling pathways during human islet preparation has a negative effect on the prospects of the graft survival following islet transplantation (Abdelli et al. 2004, Aikin et al. 2004). The capacity of the CRF family to significantly reduce apoptosis in human islets following isolation indicates a therapeutic potential of these peptides in protection of islet survival. Our data prompt further analysis exploring the potential use of CRFR agonists as a therapeutic approach aimed at enhancing β-cell survival, thereby reducing or delaying cytokine-mediated β-cell destruction in the development of type 1 and type 2 diabetes.

Declaration of interest

L B, G L C, M M, T M, M O H, and N B have nothing to declare. W W V was a co-founder, member of the Board of Directors, and a shareholder of Neurocrine Biosciences, a company that is developing small molecule agonists of corticotropin-releasing factor.

Funding

This work was supported in part by The Alfred Benzon Foundation, the Clayton Medical Research Foundation, Inc., the Juvenile Diabetes Research Foundation, the National Institute of Diabetes, and Digestive and Kidney Diseases (NIDDK) grant PO1 DK026741-30, The Danish Council for Independent Research, Medical Sciences and The Novo Nordisk Foundation. G L C hold a postdoctoral grant from the Danish Diabetes Academy.

Author contribution statement

L B designed the study, performed experiments, evaluated data, and wrote the manuscript. G L C performed experiments, evaluated data, and wrote the manuscript. M M, TM, M O H, and N B evaluated data and participated in writing the manuscript, and W W V designed the study and evaluated data.

Acknowledgements

Human islets were obtained courtesy of the Islet cell Resource Basic Science Islets Distribution Program. The authors thank Jean Rivier and Judit Ercegjyi (The Salk Institute) for providing the peptides used in this study and Helle Fjordvang for excellent technical assistance. This article is dedicated to W W V, PhD, who passed away unexpectedly on January 3, 2012 while this work was in progress. Dr W W V was an extraordinary mentor and contributed greatly to the understanding of CRF the effects of/urocortins in β-cells and islets.

References


Brar BK, Stephanou A, Knight R & Latchman DS 2002 Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. Journal of Molecular and Cellular Cardiology 34 483–492. (doi:10.1006/jmcc.2002.1529)


Hsu SY & Hsueh AJ 2001 Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. *Nature Medicine* 7 605–611. (doi:10.1038/87936)


hypoxia and cytokines are augmented by CREB. *Endocrinology* 153, 1116–1128. (doi:10.1210/en.2011-1895)


Withers DJ, Burks DJ, Towery HH, Altamuro SL, Flint CL & White MF 1999 Irs-2 coordinates Igf-1 receptor-mediated β-cell development and peripheral insulin signaling. *Nature Genetics* 23, 32–40. (doi:10.1038/12631)


Received in final form 7 October 2014
Accepted 16 October 2014
Accepted Preprint published online 16 October 2014